Literature DB >> 28978582

Posterior reversible encephalopathy syndrome in a postpartum woman with acute lymphoblastic leukaemia after intrathecal methotrexate.

Craig Mescher1, Arne Slungaard1.   

Abstract

Posterior reversible encephalopathy syndrome (PRES) is the most common neurological complication occurring in children undergoing induction chemotherapy for acute lymphoblastic leukaemia (ALL) but is increasingly recognised to occur in adults as well. Here, we report a woman who presented with B-cell ALL (B-ALL) at the time of delivery and developed PRES 1 day after receiving intrathecal (IT) methotrexate (MTX) that rapidly resolved. She subsequently received IT MTX without recurrence of neurological symptoms. This case represents the first case of PRES in a postpartum B-ALL patient receiving IT MTX, demonstrates that re-treatment with MTX in this case could be done safely and highlights the risk of PRES in adults treated for B-ALL. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  chemotherapy; haematology (drugs and medicines); haematology (incl blood transfusion); pregnancy; unwanted effects / adverse reactions

Mesh:

Substances:

Year:  2017        PMID: 28978582      PMCID: PMC5652517          DOI: 10.1136/bcr-2017-220429

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Posterior reversible encephalopathy syndrome and oral methotrexate.

Authors:  Caroline Hart; Michael O Kinney; Mark O McCarron
Journal:  Clin Neurol Neurosurg       Date:  2012-01-04       Impact factor: 1.876

2.  Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution.

Authors:  Rosanna Parasole; Fara Petruzziello; Giuseppe Menna; Argia Mangione; Emilio Cianciulli; Salvatore Buffardi; Luciano Marchese; Anna Nastro; Aldo Misuraca; Vincenzo Poggi
Journal:  Leuk Lymphoma       Date:  2010-06

3.  Posterior reversible encephalopathy syndrome (PRES): an unusual primary manifestation of a diffuse large B-cell lymphoma.

Authors:  Robert Patejdl; Kersten Borchert; Heike Pagumbke; Reiner Benecke; Annette Grossmann; Friedrich Prall; Christoph Kahl; Mathias Freund; Michael Schmitt; Uwe Walter
Journal:  Clin Neurol Neurosurg       Date:  2011-09-15       Impact factor: 1.876

4.  Posterior reversible encephalopathy after intrathecal methotrexate therapy in diffuse large B-cell lymphoma.

Authors:  Amit Patel; Robert Ayto; Donald H MacDonald
Journal:  Br J Haematol       Date:  2013-04-25       Impact factor: 6.998

Review 5.  Posterior reversible encephalopathy syndrome--Insight into pathogenesis, clinical variants and treatment approaches.

Authors:  Guido Granata; Antonio Greco; Giannicola Iannella; Massimo Granata; Alessandra Manno; Ersilia Savastano; Giuseppe Magliulo
Journal:  Autoimmun Rev       Date:  2015-05-18       Impact factor: 9.754

6.  Posterior reversible encephalopathy syndrome in eclamptic patients: neuroradiological manifestation, pathogenesis and management.

Authors:  Marija S Kutlesič; Ranko M Kutlesič; Goran P Koratevič
Journal:  Med Pregl       Date:  2015 Jan-Feb

7.  The role of tumor lysis in reversible posterior leukoencephalopathy syndrome.

Authors:  Emiko Kaito; Satoshi Terae; Ryoji Kobayashi; Kohsuke Kudo; Khin Khin Tha; Kazuo Miyasaka
Journal:  Pediatr Radiol       Date:  2005-03-09

8.  Posterior leukoencephalopathy following intrathecal chemotherapy with MRA-documented vasospasm.

Authors:  R D Henderson; T Rajah; A J Nicol; S J Read
Journal:  Neurology       Date:  2003-01-28       Impact factor: 9.910

9.  A reversible posterior leukoencephalopathy syndrome.

Authors:  J Hinchey; C Chaves; B Appignani; J Breen; L Pao; A Wang; M S Pessin; C Lamy; J L Mas; L R Caplan
Journal:  N Engl J Med       Date:  1996-02-22       Impact factor: 91.245

10.  Methotrexate-induced posterior reversible encephalopathy syndrome.

Authors:  E Aradillas; R Arora; J Gasperino
Journal:  J Clin Pharm Ther       Date:  2010-09-30       Impact factor: 2.512

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.